On June 3, 2021 GenesisCare—one of the leading oncology providers in the United States, Australia, Spain, and the United Kingdom—reporteded it will administer the first commercially available dose of Lantheus’ new prostate cancer imaging agent, PYLARIFY (piflufolastat F 18) Injection (Press release, Lantheus Medical Imaging, JUN 3, 2021, https://www.prnewswire.com/news-releases/lantheus-selects-genesiscare-to-administer-first-commercial-dose-of-pylarify-the-first-and-only-fda-approved-psma-pet-imaging-agent-for-men-with-prostate-cancer-301305363.html [SID1234583488]). As a fluorinated PSMA-targeted PET imaging agent, PYLARIFY helps determine and monitor the presence or absence of recurrent and/or metastatic prostate cancer (cancer that has spread throughout the body). *With more than 3.1 million men living with prostate cancer, it is the second leading cancer-related cause of death for men, and there is an urgent need to find better ways to diagnose, monitor, and cure this disease.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We continue to strive to deliver exceptional cancer treatments that offer the best possible life outcomes. This innovative new imaging agent will help us deliver meaningful prostate cancer treatment options that may significantly improve patient’s lives," said Dan Collins, Founder and CEO, GenesisCare. "Being selected by Lantheus to partner and to administer the first dose of PYLARIFY is an honor, and it’s humbling to know that GenesisCare will be potentially helping men with prostate cancer while improving access to high-quality care for our patients."

Prostate cancer is a common and usually slow-growing cancer. Over 60% of men 65+ years are eventually diagnosed with prostate cancer.[Source: American Cancer Society, Key Statistics for Prostate Cancer] Until now, testing for metastatic prostate cancer has been limited, and healthcare providers have had to rely on PSA blood tests and less sensitive imaging tests, such as bone scans and CT.

"When a prostate cancer patient has a rising PSA blood test after initial therapy, whether it is post-surgery or post-radiotherapy, we find that conventional imaging studies are often inadequate in identifying early stages of disease recurrence with any high degree of reliability or accuracy," said Dr. Kishore K. Dass, Radiation Oncologist, GenesisCare. "PSMA PET imaging allows clinicians to detect areas of early prostate cancer recurrences and thereby allows us to properly target the exact areas of tumor recurrences. The positive predictive value of PYLARIFY PET imaging over conventional imaging in men with high-risk prostate cancer will revolutionize the management of this disease while improving patient outcomes."

"Innovations such as PYLARIFY will expand our capability to care for men with prostate cancer," said Wally Curran, MD, GenesisCare Global Chief Medical Officer. "From diagnosis, active surveillance, surgery, radiation therapy, and more – GenesisCare physicians will consider those innovative approaches that are tailored to meeting each patients’ individual needs. We support breakthrough advances in diagnostics and therapeutics, and adding PYLARIFY into our available options is a natural fit."

Upon administering this first dose in Boca Raton, GenesisCare plans to continue to add the agent to a number of centers across the U.S.

"Nuclear medicine, including PYLARIFY PET imaging, is now a pivotal medical specialty that can transform patients by optimizing treatment selection," said Dr. Neal D. Shore, U.S. Chief Medical Officer of Surgery and Urology, GenesisCare. "The approval by the FDA for public use of this PET PSMA imaging agent provides critical accessibility which will improve prostate cancer patient management nationwide."

As a leading provider of oncology services globally, GenesisCare strives to ensure the best possible life outcomes for its patients by bringing integrated cancer care, research, and medical technology together for each individual. With its origins in radiation oncology, GenesisCare has, in recent years, expanded its services to include medical oncology, urology and surgery, and nuclear medicine, a rapidly developing field of oncology care.

For more information on GenesisCare, visit genesiscare.com/us (formerly 21st Century Oncology). To view the complete list of precautions GenesisCare U.S. centers are taking to ensure patient and staff safety, visit View Source

On June 3, 2021 Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, reported that Shehnaaz Suliman, M.D., MBA, M.Phil., president and chief operating officer of Alector, will participate in fireside chats at the following upcoming virtual investor conferences (Press release, Alector, JUN 3, 2021, View Source [SID1234583439]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Goldman Sachs 42nd Annual Global Healthcare Conference – Thursday, June 10, 2021, at 4:40 p.m. ET
The BofA Securities 2021 Napa Biopharma Virtual Conference – Monday, June 14, 2021, at 5:30 p.m. ET
Live webcasts of both presentations will be available on the "Events & Presentations" page within the Investors section of the Alector website at View Source Replays of the webcasts will be available on the Alector website for 30 days following the presentation dates.

On June 3, 2021 Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, reported that the company is scheduled to participate in a fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Conference on Thursday, June 10, 2021 at 4:40 p.m. ET (Press release, Magenta Therapeutics, JUN 3, 2021, View Source [SID1234583456]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the fireside chat can be accessed on the Magenta Therapeutics website at View Source The webcast replay will be available for 90 days following the event.

On June 3, 2021 Humanigen, Inc. (Nasdaq: HGEN), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab, reported it will present at the 2021 LD Micro Invitational XI, held virtually from June 8- 10, 2021 (Press release, Humanigen, JUN 3, 2021, View Source [SID1234583473]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

LD Micro is host to some of the most influential conferences in the small-cap world. Humanigen has been selected to participate in the first day of the conference, during the "Hall of Fame" session, which highlights some of the top performers since the LD Micro conference began in 2008.

Management will discuss its lead product, lenzilumab, which has been submitted for Emergency Use Authorization (EUA) to the U.S. Food and Drug Administration, in addition to providing an update on the Company’s launch preparation efforts for lenzilumab, and an overview of the Company’s other development programs.

Details for the upcoming event are below:

2021 LD Micro Invitational XI

Date: Tuesday, June 8, 2021
Time: 12:00 PM ET
Link: View Source

On June 3, 2021 Foresight Diagnostics, a privately-held cancer diagnostic company, reported that two abstracts that report the clinical performance of its minimal residual disease (MRD) detection platform in diffuse large B-cell lymphoma (DLBCL) and non-small cell lung cancer (NSCLC) were chosen for presentation at the virtual 2021 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting on June 4-8, 2021 (Press release, Foresight Diagnostics, JUN 3, 2021, View Source [SID1234583489]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The posters demonstrate the utility of Foresight Diagnostics proprietary PhasED-Seq technology to improve MRD detection rates in low disease burden settings in DLBCL and NSCLC patients.

Details of the posters to be presented:
Abstract 7565: Phased variants improve DLBCL minimal residual disease detection at the end of therapy

Detection of circulating tumor DNA (ctDNA) has prognostic value in DLBCL and could facilitate minimal residual disease (MRD) driven approaches. ctDNA detection has potential to change management of DLBCL in the clinic, however detection is still challenging in low-disease burden states (i.e., detection of MRD at the end of therapy). It is shown that phased variants (PVs) are common in B-cell lymphomas and occur in stereotyped locations, enabling an ‘off-the-shelf’ approach that does not require tumor tissue or patient-specific customization. PhasED-Seq (Phased Variant Enrichment & Detection Sequencing) can identify and track PVs for improved ctDNA MRD detection down to parts-per-million levels. The PhasED-Seq technology improves MRD detection compared to SNV-based methods at interim and end-of-treatment time-points for DLBCL.

Abstract 8518: Leveraging phased variants for personalized minimal residual disease detection in localized non-small cell lung cancer

The sensitivity of existing MRD methods that track single nucleotide variants (SNVs) is suboptimal due to the background error rates of SNVs. Phased variants (PVs) have a lower background error-rate than SNVs resulting in improved ctDNA MRD detection rates. PhasED-Seq was developed and applied to detect low-burden MRD in localized-stage lung cancer. PhasED-Seq improves MRD detection rates in lung cancer patients with low disease burden while maintaining high specificity. Phased variants were found to be common in most tumor types and can be applied to other cancers.

Due to the virtual nature of the annual meeting, pre-recorded presentations of each poster will be released for on-demand viewing on June 4, 2021 at 9:00 AM (EDT).

"We are pleased to present this compelling data on the PhasED-Seq technology at ASCO (Free ASCO Whitepaper) this year," says David Kurtz (MD/PhD), a Stanford University professor and co-founder of Foresight Diagnostics who will present the abstracts. "We show that PhasED-Seq more accurately distinguishes between patients who were cured and patients in need of additional therapy following curative intent treatment. This improved sensitivity for MRD detection in low-disease-burden settings will pave the way for adapted approaches to personalized therapy and novel clinical trial designs."

Learn more about attending the 2021 ASCO (Free ASCO Whitepaper) Annual Meeting at View Source